139 related articles for article (PubMed ID: 26174236)
1. Effects of teriparatide retreatment in a patient with β-thalassemia major.
Tournis S; Dede AD; Savvidis C; Triantafyllopoulos IK; Kattamis A; Papaioannou N
Transfusion; 2015 Dec; 55(12):2905-10. PubMed ID: 26174236
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Gomberg SJ; Wustrack RL; Napoli N; Arnaud CD; Black DM
J Clin Endocrinol Metab; 2011 Jun; 96(6):1627-32. PubMed ID: 21430030
[TBL] [Abstract][Full Text] [Related]
3. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
[TBL] [Abstract][Full Text] [Related]
4. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.
Palcu P; Dion N; Ste-Marie LG; Goltzman D; Radziunas I; Miller PD; Jamal SA
Am J Kidney Dis; 2015 Jun; 65(6):933-6. PubMed ID: 25843705
[TBL] [Abstract][Full Text] [Related]
5. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
8. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
9. [Anabolic therapy of induced osteoporosis in beta-thalassaemia major: case report and literature review].
Trotta A; Corrado A; Cantatore FP
Reumatismo; 2010; 62(2):119-26. PubMed ID: 20657889
[TBL] [Abstract][Full Text] [Related]
10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
11. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.
Devogelaer JP; Adler RA; Recknor C; See K; Warner MR; Wong M; Krohn K
J Rheumatol; 2010 Jan; 37(1):141-8. PubMed ID: 19918047
[TBL] [Abstract][Full Text] [Related]
12. Bone microarchitecture deteriorations and a fragility fracture in a patient with beta and alpha heterozygous thalassemia: a case report.
Feichtinger X; Kocijan R; Resch H; Muschitz C
Wien Klin Wochenschr; 2017 Mar; 129(5-6):212-216. PubMed ID: 27363996
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?
Tarazona-Santabalbina FJ; Aguilella-Fernández L
Aging Clin Exp Res; 2013 Oct; 25(5):605-9. PubMed ID: 24026625
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.
Gagliardi I; Celico M; Gamberini MR; Pontrelli M; Fortini M; Carnevale A; Napoli N; Zatelli MC; Ambrosio MR
Calcif Tissue Int; 2022 Jul; 111(1):56-65. PubMed ID: 35243531
[TBL] [Abstract][Full Text] [Related]
15. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
[TBL] [Abstract][Full Text] [Related]
16. [Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
Yamamoto S; Ei I; Narita I
Clin Calcium; 2016 Sep; 26(9):1301-7. PubMed ID: 27561345
[TBL] [Abstract][Full Text] [Related]
17. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
18. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
[TBL] [Abstract][Full Text] [Related]
19. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate.
Arai R; Takahashi D; Inoue M; Irie T; Asano T; Konno T; Terkawi MA; Onodera T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Jan; 18(1):24. PubMed ID: 28103867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
